📊 AI Costs Pressure Tech

Good Morning Investors,

Biotech may benefit from faster clinical trial monitoring and regulatory efficiency, which could create upside for select development stage names. On the other hand, rising AI infrastructure costs and compute bottlenecks are becoming a growing headwind for smaller tech firms trying to compete in capital intensive markets.

Materials and industrial names also face uncertainty, as input costs and pricing volatility continue to move through supply chains. That could pressure margins for weaker operators while benefiting companies with stronger pricing power or direct commodity exposure.

Energy, commodities, and catalyst driven biotech names remain the more attractive pockets of the market, while funding sensitive growth stocks and speculative names continue to face a tougher backdrop.

Matthias Schneider
Editor at Analytica Investor